Get notified when SILO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRisk Profile Improvements
- Material Weakness (removed) — Prior disclosure described ongoing remediation of material weaknesses in segregation of duties and bank reconciliation; current filing contains no such language, suggesting remediation complete though not explicitly stated.
SILO pivots to crypto & AI, delays drug IND, terminates key license amid control fixes
Filed May 14, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 9, 2025 · ~2 min read
Key Changes
-
high
Company adopted cryptocurrency treasury strategy in Aug 2025, now holds $173k in Bitcoin, Ethereum, and Solana; crypto losses totaled $83k in Q1 2026, contributing to 60% increase in net loss to $1.6M.
MD&A: Cryptocurrency Strategy verify on EDGAR → -
high
Acquired AI software (qwikagents.com) for 2.1M shares valued at $714k, immediately expensed as R&D; formed Qwikagentsai Inc. subsidiary in April 2026 to develop AI agent platforms.
MD&A: AI Software Acquisition verify on EDGAR → -
high
Terminated UMB license for SPU-16 (MS treatment) in July 2025, replaced with temporary option expiring March 31, 2026; company must exercise option and pay $1k fee to regain commercial rights.
MD&A: UMB License Termination verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FNGR 10-Q) is open in full — no account needed.
Partner
Trade SILO commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify